Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis最新文献_第6页

Continuous hemofiltration/hemodiafiltration in critical care. 持续血液滤过/血液滤过在重症监护中的应用。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00431.X

S. Oda, H. Hirasawa, H. Shiga, K. Nakanishi, K. Matsuda, Masataka Nakamura

{"title":"Continuous hemofiltration/hemodiafiltration in critical care.","authors":"S. Oda, H. Hirasawa, H. Shiga, K. Nakanishi, K. Matsuda, Masataka Nakamura","doi":"10.1046/J.1526-0968.2002.00431.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00431.X","url":null,"abstract":"Continuous hemofiltration and continuous hemodiafiltration (CHF/CHDF) were developed as continuous renal replacement therapy for patients with severe conditons and has come to be widely performed mainly in critical care, taking the place of intermittent hemodialysis. The membrane pore size of a hemofilter used for CHF/CHDF allows passage of substances ranging from 30,000 to 50,000 Da, and the method for solute removal in CHF/CHDF employs the principle of convection, which is advantageous for removing middle- to high-molecular-weight substances. As apheresis therapy to remove pathogenic substances in blood, CHF/CHDF is therefore being investigated for its possible effect on various morbid conditions. It has recently been found that CHF/CHDF removes humoral mediators including cytokines, particularly in severe systemic inflammatory response syndromes such as septic shock and severe acute pancreatitis. CHF/CHDF is thus beginning to be performed for the prevention and treatment of organ dysfunction secondary to septic shock, trauma, or acute pancreatitis. CHF/CHDF is also efficacious as artificial liver support in preventing adverse effects caused by plasma exchange (PE) and for continuous removal of hepatic coma-inducing substances. CHF/CHDF is effective for various morbid conditions not only as renal replacement therapy, but also as apheresis therapy and is expected to be applied more widely in critical care in the future.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"76 1","pages":"193-8"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75713224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 62

Continuous hemodiafiltration with polymyxin-B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. 多粘菌素- b固定纤维持续血液滤过治疗脓毒症合并急性肾功能衰竭是有效的。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00416.X

Hiromichi Suzuki, H. Nemoto, H. Nakamoto, H. Okada, S. Sugahara, Y. Kanno, K. Moriwaki

{"title":"Continuous hemodiafiltration with polymyxin-B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure.","authors":"Hiromichi Suzuki, H. Nemoto, H. Nakamoto, H. Okada, S. Sugahara, Y. Kanno, K. Moriwaki","doi":"10.1046/J.1526-0968.2002.00416.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00416.X","url":null,"abstract":"The aim of this study was first, to evaluate the effects of continuous hemodiafiltration (CHDF) alone or combined with CHDF and polymyxin-B immobilized fiber (PMX) on survival rates of patients with sepsis and acute renal failure, and second, to evaluate the changes in plasma levels of inflammatory cytokines before and after treatment with CHDF and PMX and CHDF alone in these patients. Forty-eight patients with septic shock and acute renal failure were enrolled in this study. The survival rate of all patients at 28 days was 25% for those with CHDF and 75% for those with PMX and CHDF treatment. Combination treatment produced a significant reduction of plasma levels of endotoxin and interleukin-6 compared to the basal values and to the treatment with CHDF alone. From these data, it is suggested that the combined therapy with PMX and CHDF is effective in improvement of survival rate of patients with septic shock and acute renal failure.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"1 1","pages":"234-40"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74687501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 66

Affinity hemodialysis for antiviral therapy. I. Removal of HIV-1 from cell culture supernatants, plasma, and blood. 亲和力血液透析用于抗病毒治疗。1 .从细胞培养上清、血浆和血液中去除HIV-1。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00407.X

R. Tullis, R. Duffin, M. Zech, J. Ambrus

{"title":"Affinity hemodialysis for antiviral therapy. I. Removal of HIV-1 from cell culture supernatants, plasma, and blood.","authors":"R. Tullis, R. Duffin, M. Zech, J. Ambrus","doi":"10.1046/J.1526-0968.2002.00407.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00407.X","url":null,"abstract":"We tested an affinity hemodialysis technique designed to efficiently remove HIV and toxic viral proteins from blood. Miniature polyethersulfone hollow-fiber dialysis cartridges (200-500 nm pore) were packed with anti-HIV antibodies covalently coupled to agarose beads and sealed inside the cartridge. Cell culture fluids, plasma, or infected blood (7-15 ml) containing HIV-1 were circulated over the cartridge at 0.7-10 ml/min and the rate of removal of HIV measured by PCR and p24 ELISA. The technique removed up to 98% of HIV-1 particles from cell culture supernatants. Affinity hemodialysis also efficiently captured cultured HIV from human blood plasma (90%) and native HIV from infected blood (83% to 100%). Viral capture followed first-order kinetics (t(1/2) = 2.8 h). Variations in antibody type, matrix linkage (protein G versus direct coupling), bead pore size, and temperature of operation (25-37 degrees C) had only small effects. Although some binding was nonspecific, direct binding to the immobilized antibodies appeared to be the predominant mechanism.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"53 1","pages":"213-20"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79638453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 38

Hemoadsorption in critical care. 重症监护中的血液吸附。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00430.X

T. Ikeda

引用次数: 10

A patient with severe acute pancreatitis successfully treated with a new critical care procedure. 重症急性胰腺炎患者成功治疗与新的重症监护程序。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00435.X

T. Moriguchi, H. Hirasawa, S. Oda, H. Shiga, K. Nakanishi, K. Matsuda, Masataka Nakamura, K. Yokohari, Takeshi Hirano, Y. Hirayama, Eizo Watanabe

{"title":"A patient with severe acute pancreatitis successfully treated with a new critical care procedure.","authors":"T. Moriguchi, H. Hirasawa, S. Oda, H. Shiga, K. Nakanishi, K. Matsuda, Masataka Nakamura, K. Yokohari, Takeshi Hirano, Y. Hirayama, Eizo Watanabe","doi":"10.1046/J.1526-0968.2002.00435.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00435.X","url":null,"abstract":"It has been accepted widely that excessive humoral mediators play important roles in the pathogenesis of organ failure in patients with severe acute pancreatitis (SAP) and that infection of the pancreas due to bacterial translocation (BT) is the most frequent cause of death in SAP. On the other hand, it has been reported that continuous hemodiafiltration (CHDF) removes humoral mediators on hypercytokinemic patients such as those with systemic inflammatory response syndrome. Furthermore, several clinical studies have demonstrated that selective digestive decontamination (SDD) effectively eliminates aerobic Gram-negative bacteria from the intestinal tract and reduces the incidence of septic complications in SAP. Herein we report a case of SAP who was treated successfully with intensive care including CHDF and SDD. Thus, this case report suggests that CHDF aimed at removing causative humoral mediators and SDD for the prevention of BT are useful new tools for the management of SAP.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"26 1 1","pages":"221-4"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76031943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

On-line hemodiafiltration in critical care. 危重监护中的在线血液滤过。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00432.X

H. Kawanishi

引用次数: 5

Effects of direct adsorption of lipoproteins apheresis on lipoproteins, low-density lipoprotein subtypes, and hemorheology in hypercholesterolemic patients with coronary artery disease. 直接吸附脂蛋白分离对冠心病高胆固醇血症患者脂蛋白、低密度脂蛋白亚型和血液流变学的影响

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-04-01 DOI: 10.1046/J.1526-0968.2002.00366.X

C. Otto, H. Geiss, E. Laubach, P. Schwandt

{"title":"Effects of direct adsorption of lipoproteins apheresis on lipoproteins, low-density lipoprotein subtypes, and hemorheology in hypercholesterolemic patients with coronary artery disease.","authors":"C. Otto, H. Geiss, E. Laubach, P. Schwandt","doi":"10.1046/J.1526-0968.2002.00366.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00366.X","url":null,"abstract":"Direct adsorption of lipoproteins (DALI) apheresis has been shown to reduce effectively low-density lipoprotein (LDL) cholesterol and lipoprotein (a) concentrations. However, the effects on nontraditional risk indicators such as hemorheology and LDL subtypes have not been investigated so far. Five patients (2 women, 3 men, age 53 +/- 8 years) with coronary artery disease and severe LDL hypercholesterolemia regularly treated with other LDL apheresis devices entered the study and were then treated with DALI for the first time. Hemorheological and lipoprotein parameters were measured before and immediately after the initial DALI apheresis as well as before the fourth DALI apheresis. Compared to baseline (before the first DALI apheresis), the following parameters were significantly improved (p < 0.05) after the first DALI apheresis: LDL cholesterol (69 +/- 28 versus 208 +/- 82 mg/dl) and cholesterol in each LDL subfraction as well as plasma viscosity (1.23 +/- 0.04 versus 1.37 +/- 0.06 mPa), C-reactive protein, native blood viscosity, red cell aggregation, and red cell deformability. When parameters before the fourth DALI apheresis were compared to baseline, LDL cholesterol was still lower, and red cell deformability was still improved while cholesterol in each subfraction showed a statistical trend to lower concentrations (0.08 < p < 0.14). In conclusion, DALI apheresis not only reduces LDL cholesterol but also induced a significant reduction of cholesterol in all LDL subfractions and improved various hemorheological parameters.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"8 1","pages":"130-5"},"PeriodicalIF":0.0,"publicationDate":"2002-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81363997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

Adsorption of endotoxin by beta2-microglobulin adsorbent column (Lixelle): the new approach for endotoxinemia. β -微球蛋白吸附柱(Lixelle)吸附内毒素:内毒素血症的新方法。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-04-01 DOI: 10.1046/J.1526-0968.2002.00412.X

K. Tsuchida, Y. Takemoto, K. Sugimura, R. Yoshimura, K. Yamamoto, T. Nakatani

{"title":"Adsorption of endotoxin by beta2-microglobulin adsorbent column (Lixelle): the new approach for endotoxinemia.","authors":"K. Tsuchida, Y. Takemoto, K. Sugimura, R. Yoshimura, K. Yamamoto, T. Nakatani","doi":"10.1046/J.1526-0968.2002.00412.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00412.X","url":null,"abstract":"We previously reported that Lixelle, which was used for beta2-microglobulin (BMG) adsorption columns, could adsorb not only BMG but also inflammatory cytokines. We became interested in the application of Lixelle for patients with endotoxinemia and researched its ability to adsorb microorganism components in vitro using lipopolysaccharide (LPS) (Escherichia coli B8), endotoxin (ET) contaminated water. The initial concentrations of each water solution were LPS (ET 29,135 EU/L) and contaminated water (ET 3,523 EU/L) whole blood solution was LPS (ET 1,197.6 EU/L). Each 2.5 ml of the stock solution and adjusted diluted solutions contained 0.5 ml of Lixelle beads. After shaking at 37 degrees C for 2 h, ET in the solutions was determined using the endotoxin specific-limulus amebocyte lysate method. The results revealed that even though ET concentrations in LPS and contaminated water incubated in water solution and in whole blood were high, the samples containing Lixelle beads showed significant decreases. Thus, Lixelle beads can adsorb not only BMG but also microorganism components such as LPS and ET. These findings together with the ability of Lixelle to adsorb ET show the possibility of the application for treatment of endotoxinemia.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"23 1","pages":"116-8"},"PeriodicalIF":0.0,"publicationDate":"2002-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74798782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

Reactive hemophagocytic syndrome associated with thrombotic thrombocytopenic purpura during therapeutic plasma exchange. 治疗血浆交换期间与血栓性血小板减少性紫癜相关的反应性噬血细胞综合征。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-04-01 DOI: 10.1046/J.1526-0968.2002.00362.X

E. Kfoury Baz, Abdel Razzak A Mikati, N. Kanj

{"title":"Reactive hemophagocytic syndrome associated with thrombotic thrombocytopenic purpura during therapeutic plasma exchange.","authors":"E. Kfoury Baz, Abdel Razzak A Mikati, N. Kanj","doi":"10.1046/J.1526-0968.2002.00362.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00362.X","url":null,"abstract":"Hemophagocytic lymphohistiocytosis (HLH) is characterized by fever, cytopenia, splenomegaly, and lymphohistiocytic proliferation with hemophagocytosis. Sporadic, familial, and reactive HLH varieties exist. The latter, also termed the reactive hemophagocytic syndrome (RHS), has been associated with a variety of infectious and noninfectious etiologies. Activation of monocytes in RHS is due to stimulation by high levels of activating cytokines. RHS has not been associated previously with thrombotic thrombocytopenic purpura (TTP). TTP is a multisystem disorder characterized by consumptive thrombocytopenia, microangiopathic hemolytic anemia, neurologic symptoms, renal impairment, and fever. We report on a 33 year old male patient with a classic picture of TTP who initially responded to therapeutic plasma exchange but then became refractory to treatment and developed RHS. It is likely that a specific pathophysiology involving the activation of neutrophils during TPE is present for the development of cytokine-induced hemophagocytosis during TTP treatment. The consequent development of RHS possibly caused early TTP relapse.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"4 1","pages":"159-62"},"PeriodicalIF":0.0,"publicationDate":"2002-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88747434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

The beneficial effects of lymphocytapheresis for treatment of nephrotic syndrome. 淋巴细胞摘除术治疗肾病综合征的有益效果。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-04-01 DOI: 10.1046/J.1526-0968.2002.00351.X

H. Yokoyama, M. Shimizu, T. Wada, K. Yoshimoto, Y. Iwata, Kazuaki Shimizu, N. Sakai, K. Furuichi, Y. Hisada, H. Takakuwa, Ken‐ichi Kobayashi

{"title":"The beneficial effects of lymphocytapheresis for treatment of nephrotic syndrome.","authors":"H. Yokoyama, M. Shimizu, T. Wada, K. Yoshimoto, Y. Iwata, Kazuaki Shimizu, N. Sakai, K. Furuichi, Y. Hisada, H. Takakuwa, Ken‐ichi Kobayashi","doi":"10.1046/J.1526-0968.2002.00351.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00351.X","url":null,"abstract":"A considerable permeability factor (or factors) derived from circulating T cells has a crucial role in proteinuria of nephrotic syndrome (NS). We attempted to remove pathogenic T cells through lymphocytapheresis (LCAP) in 6 patients with primary NS, 2 patients with minimal change nephrotic syndrome (MCNS), 2 patients with focal segmental glomerulosclerosis (FSGS), 1 patient with membranous nephropathy (MN), and 1 patient with MN and FSGS using Cellsorba (Asahi Medical Co., Osaka, Japan). LCAP was performed 2 times in 2 consecutive weeks and was followed with corticosteroid therapy with or without cyclosporine A in 5 patients. Two patients with MCNS, 1 with FSGS, and 1 with MN and FSGS showed a dramatic decrease of proteinuria (-30% and -94%) in their urine protein/creatinine ratio. Three out of 4 patients had a complete or partial remission (proteinuria <1g/day) within 8 weeks following immunosuppressive therapy. During the LCAP, T cells, especially activated T cells, decreased significantly in the response group. The other 2 patients, 1 with FSGS and 1 with MN, however, had no response to LCAP and following immunosuppressive therapy or low-density lipoprotein apheresis and suffered from end-stage renal failure or death by pneumonia. These results suggested that LCAP might have a beneficial effect on the treatment of NS, especially MCNS and in some patients with FSGS, despite varying responses to LCAP and concomitant immunosuppressive therapy.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"171 1","pages":"167-73"},"PeriodicalIF":0.0,"publicationDate":"2002-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84008369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10